|
|
Profile
|
Delegates :
Shiro Akinaga |
|
Incorporated :
June 14 , 1996 |
Paid in Capital :
142 Million yen |
Employees :
28 人 |
Address :
Atago Green Hills MORI Tower 26F 2-5-1 Atago, Minato-ku TOKYO
〒105-6226
|
TEL/FAX :
+81-3-6432-4791 / +81-3-6432-4794 |
URL：
https://www.nanomrna.co.jp/en/ |
Attachment :
|
Mission/Background :
2023, we pivoted to the new business model of mRNA drug discovery, and changed our company name accordingly, adopting NANO MRNA Co., Ltd. from NanoCarrier Co., Ltd.
We are promoting activities with the vision of " mRNA medicine IP generator as a platform company that connects drug discovery seeds with medical and drug development needs".
There are very few companies in Japan involved in the development of therapeutic drugs using mRNA, and we are developing an mRNA drug discovery platform business as a pioneer in Japan.
The company is actively promoting joint research with industry and academia that have ideas and technologies related to mRNA medicine, creating new mRNA medicine development candidates one by one, and preparing packages to enter clinical trials. |
|
Technology & Business
|
● Generate intellectual property (IP) on mRNA therapeutics in-house and in collaboration with companies and academia, and license out drug candidates
● Contract research and development of mRNA vaccines and mRNA therapeutics for domestic and foreign companies
mRNA drug discovery platform of NANO MRNA
● the only company in Japan with proven expertise
● multiple promising development candidates
● value chain encompasses the process from seed to development candidate
● comprehensive range of DDS (Drug Delivery System) selection solutions based on our experience
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
mRNA: RUNX1
|
Preclinical
|
Osteoarthritis
|
|
ASO: TUG1
|
Phase1
|
GBM
|
|
ｍRNA Drug Discovery
|
Discovery
|
Allergy, Ophthalmic
|
Kao Corporation, SENJU
|
Contract research
|
Launched
|
Vaccine
|
Drug Discovery entrusted from Companies/Academia, etc.
|
|
|
|
|
|
Alliance strategy
|
We possess the high quality value chain required for mRNA drug discovery.
[Select molecular target/disease → Design mRNA design/DDS → Conduct pharmacology, kinetics and distribution, and initial toxicity studies].
We aim to expand the number of partner companies using our mRNA drug discovery research and development model by utilising our experience and expertise in drug development.
|
|
|